LIGAND PHARMACEUTICALS INC — Director's Dealing 2021

Nov 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-11-11

Reporting Person: FOEHR MATTHEW W (President and COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-11	Common Stock	M	1028	$100.38	Acquired	166525	Direct
2021-11-11	Common Stock	M	11160	$21.92	Acquired	177685	Direct
2021-11-11	Common Stock	S	11160	$163.0157	Disposed	166525	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-11	Employee Stock Option (right to buy)	$21.92	M	11160	Disposed	2023-02-15	Common Stock (11160)	Direct
2021-11-11	Employee Stock Option (right to buy)	$100.38	M	1028	Disposed	2027-02-24	Common Stock (1028)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.41 to $166.38, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.

F3: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/24/2017.